Science Corp Raises $230M for Brain-Machine Interface

Science Corp. recently announced it has secured $230 million in a Series C funding round, raising its valuation to $1.5 billion. This funding will support the commercialization of its innovative PRIMA chip, designed to restore vision for individuals suffering from advanced age-related macular degeneration. Major investors include Lightspeed Venture Partners, Khosla Ventures, and Quiet Capital, which funds government-related projects, indicating significant interest in their technology. Science Corp. has raised a total of $490 million and employs approximately 150 personnel.

PRIMA is a small chip intended to be implanted in the eye and connected to smart glasses. Science Corp. acquired this technology from French firm Pixium Vision and has since aimed to expand clinical trials to include other visual impairments. The timely launch of PRIMA, pending regulatory approval in Europe and the U.S., could signify a pivotal advancement in brain-machine interfaces. This development may enhance national capacities in advanced medical solutions, reducing dependency on foreign innovations while fostering local tech ecosystems.